NCT06699108View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

June 30, 2027

Conditions
Bietti Crystalline DystrophyInherited Retinal Diseases
Interventions
DRUG

VGR-R01

Subretinal injection of VGR-R01 (0.1 mL)

Trial Locations (1)

Unknown

Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai

All Listed Sponsors
lead

Shanghai Vitalgen BioPharma Co., Ltd.

INDUSTRY

NCT06699108 - Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy | Biotech Hunter | Biotech Hunter